AMG 827

DRUG3 trials

Sponsors

Amgen, Bausch Health Americas, Inc.

Conditions

AsthmaPsoriasisRheumatoid Arthritis

Phase 2

Safety and Efficacy of AMG 827 in Subjects With RA

TerminatedNCT01059448

AmgenRheumatoid Arthritis

Start: 2010-06-03End: 2011-04-05Updated: 2022-02-28

Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis

TerminatedNCT01101100

Bausch Health Americas, Inc.Psoriasis

Start: 2010-04-30End: 2015-09-30Updated: 2019-07-30

A Study to Evaluate the Dosing of AMG 827 for Subjects With Inadequately Controlled Asthma

CompletedNCT01199289

Start: 2010-10-04End: 2011-12-21Updated: 2021-11-26

Related Papers

Malignancy Rates in Brodalumab Clinical Studies for Psoriasis

American Journal of Clinical Dermatology2020-03-2318 citations

Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study

American Journal of Clinical Dermatology2019-09-0940 citations

Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human Anti–IL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma

American Journal of Respiratory and Critical Care Medicine2013-11-07650 citations